RecruitingPhase 2NCT04585477
Adjuvant ctDNA-Adapted Personalized Treatment in Early Stage NSCLC (ADAPT-E)
Studying Mucolipidosis type II
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Stanford University
- Principal Investigator
- Joel W Neal, MD,PhDStanford Universiy
- Intervention
- AVENIO ctDNA Surveillance Kit(device)
- Enrollment
- 80 target
- Eligibility
- 18 years · All sexes
- Timeline
- 2021 – 2026
Study locations (1)
- Stanford University, Stanford, California, United States
Collaborators
AstraZeneca
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04585477 on ClinicalTrials.govOther trials for Mucolipidosis type II
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE1, PHASE2NCT07012031Sotorasib in Combination With Trastuzumab Deruxtecan for the Treatment of Locally Advanced and Metastatic Non-small Cell Lung Cancer With a KRAS G12C MutationNational Cancer Institute (NCI)
- RECRUITINGPHASE1NCT07377435DC/MM Fusion Vaccine With BCMA CAR-T in R/R MMDavid Avigan
- RECRUITINGPHASE1NCT07032714Mezigdomide and Talquetamab in Relapsed and Refractory Multiple MyelomaMassachusetts General Hospital
- RECRUITINGPHASE1, PHASE2NCT06903377Study of ZG005 Combined With Gecacitinib in Patients With Advanced Non-Small Cell Lung CancerSuzhou Zelgen Biopharmaceuticals Co.,Ltd
- RECRUITINGPHASE1NCT06994143A Study of CLN-978, a Subcutaneously Administered CD19-directed T Cell Engager, in Subjects With Rheumatoid ArthritisCullinan Therapeutics Inc.
- RECRUITINGPHASE1NCT06861543The Purpose of This Study is to Evaluate the Safety, Tolerability and Efficacy of TMT101 Injection Monotherapy in Patients With Advanced Pancreatic Cancer or Non-small Cell Lung Cancer(NSCLC)Peking Union Medical College Hospital
- RECRUITINGPHASE1, PHASE2NCT06083207A Study of IBI3003 in Subjects With Relapsed or Refractory Multiple MyelomaInnovent Biologics (Suzhou) Co. Ltd.
- RECRUITINGPHASE1, PHASE2NCT06495723Polyspecific Antibodies in Lymphoproliferative T-cell DisordersXenothera SAS